United States: The U.S. Food and Drug Administration (FDA) has already approved a new RSV vaccine from Pfizer for adults aged 18 to 59 who are at increased risk of getting sick it can say properly ill from RSV, a virus that can cause very severe lung problems.
In the month of June, the Centers for Disease Control and Prevention (CDC) updated its guidelines, recommending RSV vaccines for older adults but not here and yet for those under 60. This approval is an important step in helping more people protect themselves from RSV!
As reported by Reuters, after a long wait, the CDC has recently issued recommendations for the administration of RSV vaccines to adults, 75 years or more; and those between 60-74 years with underlying medical conditions that increase the risk of severe disease caused by RSV.
However, the second process is the CDC has to approve the shots for that age group is also essential before getting shots for the age group.
Abrysvo approval in adults 18 to 59 years Earlier this year Regeneron gained US approval for the vaccine, Abrysvo, through a late-stage trial in immunocompromised adults aged 18 years and older of two doses of this vaccine.
The new data indicate that the vaccine was safe and was tolerated well among participants in the trial and in other studies of the vaccine, according to Pfizer.
CDC’s advisers are due to discuss Pfizer’s data this week, although they will not be voting for the expansion of the recommendations.
Pfizer’s vaccine only works for people 60 years and above and pregnant women in the middle of the third trimester to shield their newborns.
RSV is an important cause of colds but is a major cause of pneumonia in children under two and the elderly; 177,000 hospitalizations and 14,000 deaths result from this in the United States each year.
However, the CDC still needs to approve the shots for this age group before they can be administered. Earlier this year, another company, Regeneron, gained U.S. approval for its RSV vaccine called Abrysvo for adults 18 and older, based on a late-stage trial. Pfizer’s vaccine has shown to be safe and well-tolerated among trial participants.